HEALTH

PositiveID announces partnerships with DRI, Schneider Children’s

BY Allison Cerra

DELRAY BEACH, Fla. — In an effort to continue developing and studying its diabetes management products, PositiveID has teamed up with the Diabetes Research Institute at the University of Miami and Schneider Children’s Medical Center of Israel.

"We believe that joining forces with the DRI and Schneider Children’s, two of the world’s foremost diabetes research organizations, will enable us to accelerate the remaining development and study of our noninvasive diabetes management projects, and ultimately bring these groundbreaking products to market," PositiveID chairman and CEO William Caragol said.

PositiveID currently is developing Easy Check, a noninvasive breath glucose detection device; GlucoChip, a continuous glucose-sensing microchip; and the iGlucose glucometer, a blood-glucose meter with PositiveID’s Food and Drug Administration-cleared iGlucose technology built inside the device.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Identigene: Resolving paternity questions a growing New Year’s resolution

BY Michael Johnsen

SALT LAKE CITY — According to a survey released by Identigene last week, more than half of adults with paternity questions have resolved to address their question in 2012. Men with paternity questions are twice as likely (51%) than women (25%) to address paternity in 2012.

Overall, as many as 11% of adults have reported they have personally been in a situation where a paternity test was appropriate; and nearly 1-in-5 (18%) said that they or a close friend or family member have questioned paternity.

The research helped to confirm a seasonal sales trend identified by Identigene in its sales of Identigene DNA paternity test — each year the company experiences a spike in first-quarter sales, which the company attributes, in part, to New Year’s resolutions.

“The new year definitely seems to trigger many adults with paternity questions to take steps to address their question,” stated Steven Smith, executive director for Identigene.

Although the specific reasoning for paternity testing varies from person to person, the benefits of confirming paternity are multifaceted and far reaching. In the survey, 3-in-4 adults (77%) said they believe it’s important for a child to know his or her biological father.

From emotional and health benefits to financial welfare, paternity answers can have many important and positive impacts for children. “Knowledge is empowering,” Smith said. “It’s important for children and families to know the truth about paternity, as it can impact a child’s health, as well as their emotional health and well-being for years to come.” 

 


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Perrigo announces summertime availability of desloratadine in Rx and OTC

BY Michael Johnsen

ALLEGAN, Mich. — Perrigo last week announced that it has received final Food and Drug Administration approval for its generic prescription allergy remedy desloratadine 5 mg, the generic equivalent to Schering-Plough’s Clarinex.

Under the terms of a patent-infringement suit settlement, Perrigo can commercially launch its generic desloratadine product July 1. The new product launch may be a prescription or over-the-counter product, depending on its status at the time of launch, Perrigo stated.

Clarinex sales were approximately $185 million, according to Perrigo, citing Wolters Kluwer data.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?